Literature DB >> 27795727

Low-frequency KRAS mutations are prevalent in lung adenocarcinomas.

Meagan B Myers1, Karen L McKim1, Fanxue Meng1, Barbara L Parsons1.   

Abstract

AIM: This study quantified low-frequency KRAS mutations in normal lung and lung adenocarcinomas, to understand their potential significance in the development of acquired resistance to EGFR-targeted therapies. MATERIALS &
METHODS: Allele-specific Competitive Blocker-PCR was used to quantify KRAS codon 12 GAT (G12D) and GTT (G12V) mutation in 19 normal lung and 21 lung adenocarcinoma samples.
RESULTS: Lung adenocarcinomas had KRAS codon 12 GAT and GTT geometric mean mutant fractions of 1.94 × 10-4 and 1.16 × 10-3, respectively. For 76.2% of lung adenocarcinomas, the level of KRAS mutation was greater than the upper 95% confidence interval of that in normal lung.
CONCLUSION: KRAS mutant tumor subpopulations, not detectable by DNA sequencing, may drive resistance to EGFR blockade in lung adenocarcinoma patients.

Entities:  

Keywords:  carcinogenesis; epidermal growth factor receptor; mutation; mutation detection; non-small-cell lung cancer; oncogene; oncogene-induced senescence; personalized medicine; polyclonal tumor origin; targeted molecular therapy

Year:  2015        PMID: 27795727      PMCID: PMC5084916          DOI: 10.2217/pme.14.69

Source DB:  PubMed          Journal:  Per Med        ISSN: 1741-0541            Impact factor:   2.512


  56 in total

1.  Fetal-juvenile origins of point mutations in the adult human tracheal-bronchial epithelium: absence of detectable effects of age, gender or smoking status.

Authors:  Hiroko Sudo; Xiao-Cheng Li-Sucholeiki; Luisa A Marcelino; Amanda N Gruhl; Pablo Herrero-Jimenez; Helmut Zarbl; James C Willey; Emma E Furth; Stephan Morgenthaler; Hilary A Coller; Per O Ekstrom; Ray Kurzweil; Elena V Gostjeva; William G Thilly
Journal:  Mutat Res       Date:  2008-09-09       Impact factor: 2.433

Review 2.  Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer.

Authors:  Helena Linardou; Issa J Dahabreh; Dimitra Kanaloupiti; Fotios Siannis; Dimitrios Bafaloukos; Paris Kosmidis; Christos A Papadimitriou; Samuel Murray
Journal:  Lancet Oncol       Date:  2008-09-17       Impact factor: 41.316

3.  Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib.

Authors:  David A Eberhard; Bruce E Johnson; Lukas C Amler; Audrey D Goddard; Sherry L Heldens; Roy S Herbst; William L Ince; Pasi A Jänne; Thomas Januario; David H Johnson; Pam Klein; Vincent A Miller; Michael A Ostland; David A Ramies; Dragan Sebisanovic; Jeremy A Stinson; Yu R Zhang; Somasekar Seshagiri; Kenneth J Hillan
Journal:  J Clin Oncol       Date:  2005-07-25       Impact factor: 44.544

4.  Knock-in of oncogenic Kras does not transform mouse somatic cells but triggers a transcriptional response that classifies human cancers.

Authors:  Sabrina Arena; Claudio Isella; Miriam Martini; Ario de Marco; Enzo Medico; Alberto Bardelli
Journal:  Cancer Res       Date:  2007-09-15       Impact factor: 12.701

5.  Distinctive characteristics of non-small cell lung cancer (NSCLC) in the young: a surveillance, epidemiology, and end results (SEER) analysis.

Authors:  Janakiraman Subramanian; Daniel Morgensztern; Boone Goodgame; Maria Q Baggstrom; Feng Gao; Jay Piccirillo; Ramaswamy Govindan
Journal:  J Thorac Oncol       Date:  2010-01       Impact factor: 15.609

6.  K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

Authors:  Christos S Karapetis; Shirin Khambata-Ford; Derek J Jonker; Chris J O'Callaghan; Dongsheng Tu; Niall C Tebbutt; R John Simes; Haji Chalchal; Jeremy D Shapiro; Sonia Robitaille; Timothy J Price; Lois Shepherd; Heather-Jane Au; Christiane Langer; Malcolm J Moore; John R Zalcberg
Journal:  N Engl J Med       Date:  2008-10-23       Impact factor: 91.245

7.  Somatic mutations affect key pathways in lung adenocarcinoma.

Authors:  Li Ding; Gad Getz; David A Wheeler; Elaine R Mardis; Michael D McLellan; Kristian Cibulskis; Carrie Sougnez; Heidi Greulich; Donna M Muzny; Margaret B Morgan; Lucinda Fulton; Robert S Fulton; Qunyuan Zhang; Michael C Wendl; Michael S Lawrence; David E Larson; Ken Chen; David J Dooling; Aniko Sabo; Alicia C Hawes; Hua Shen; Shalini N Jhangiani; Lora R Lewis; Otis Hall; Yiming Zhu; Tittu Mathew; Yanru Ren; Jiqiang Yao; Steven E Scherer; Kerstin Clerc; Ginger A Metcalf; Brian Ng; Aleksandar Milosavljevic; Manuel L Gonzalez-Garay; John R Osborne; Rick Meyer; Xiaoqi Shi; Yuzhu Tang; Daniel C Koboldt; Ling Lin; Rachel Abbott; Tracie L Miner; Craig Pohl; Ginger Fewell; Carrie Haipek; Heather Schmidt; Brian H Dunford-Shore; Aldi Kraja; Seth D Crosby; Christopher S Sawyer; Tammi Vickery; Sacha Sander; Jody Robinson; Wendy Winckler; Jennifer Baldwin; Lucian R Chirieac; Amit Dutt; Tim Fennell; Megan Hanna; Bruce E Johnson; Robert C Onofrio; Roman K Thomas; Giovanni Tonon; Barbara A Weir; Xiaojun Zhao; Liuda Ziaugra; Michael C Zody; Thomas Giordano; Mark B Orringer; Jack A Roth; Margaret R Spitz; Ignacio I Wistuba; Bradley Ozenberger; Peter J Good; Andrew C Chang; David G Beer; Mark A Watson; Marc Ladanyi; Stephen Broderick; Akihiko Yoshizawa; William D Travis; William Pao; Michael A Province; George M Weinstock; Harold E Varmus; Stacey B Gabriel; Eric S Lander; Richard A Gibbs; Matthew Meyerson; Richard K Wilson
Journal:  Nature       Date:  2008-10-23       Impact factor: 49.962

8.  Clinical implications of KRAS mutations in lung cancer patients treated with tyrosine kinase inhibitors: an important role for mutations in minor clones.

Authors:  Antonio Marchetti; Michele Milella; Lara Felicioni; Federico Cappuzzo; Luciana Irtelli; Maela Del Grammastro; Mariagrazia Sciarrotta; Sara Malatesta; Carmen Nuzzo; Giovanna Finocchiaro; Bruno Perrucci; Donatella Carlone; Alain J Gelibter; Anna Ceribelli; Andrea Mezzetti; Stefano Iacobelli; Francesco Cognetti; Fiamma Buttitta
Journal:  Neoplasia       Date:  2009-10       Impact factor: 5.715

9.  Tumor induction by an endogenous K-ras oncogene is highly dependent on cellular context.

Authors:  Carmen Guerra; Nieves Mijimolle; Alma Dhawahir; Pierre Dubus; Marta Barradas; Manuel Serrano; Victoria Campuzano; Mariano Barbacid
Journal:  Cancer Cell       Date:  2003-08       Impact factor: 31.743

10.  Topographic analysis of K- ras mutations in histologically normal lung tissues and tumours of lung cancer patients.

Authors:  P Keohavong; H H Mady; W M Gao; J M Siegfried; J D Luketich; M F Melhem
Journal:  Br J Cancer       Date:  2001-07-20       Impact factor: 7.640

View more
  6 in total

1.  Ovarian effects of prenatal exposure to benzo[a]pyrene: Roles of embryonic and maternal glutathione status.

Authors:  Ulrike Luderer; Meagan B Myers; Malathi Banda; Karen L McKim; Laura Ortiz; Barbara L Parsons
Journal:  Reprod Toxicol       Date:  2017-03-06       Impact factor: 3.143

2.  Identification of mutant K-RAS in pituitary macroadenoma.

Authors:  Veronica Aran; Manoela Heringer; Paulo Jose da Mata; Leandro Kasuki; Renan Lyra Miranda; Felipe Andreiuolo; Leila Chimelli; Paulo Niemeyer Filho; Monica Roberto Gadelha; Vivaldo Moura Neto
Journal:  Pituitary       Date:  2021-05-05       Impact factor: 4.107

3.  Variation in organ-specific PIK3CA and KRAS mutant levels in normal human tissues correlates with mutation prevalence in corresponding carcinomas.

Authors:  Barbara L Parsons; Karen L McKim; Meagan B Myers
Journal:  Environ Mol Mutagen       Date:  2017-07-29       Impact factor: 3.216

Review 4.  An Update on Predictive Biomarkers for Treatment Selection in Non-Small Cell Lung Cancer.

Authors:  Tamkin Ahmadzada; Steven Kao; Glen Reid; Michael Boyer; Annabelle Mahar; Wendy A Cooper
Journal:  J Clin Med       Date:  2018-06-15       Impact factor: 4.241

5.  Comprehensive genomic and immunological characterization of Chinese non-small cell lung cancer patients.

Authors:  Xu-Chao Zhang; Jun Wang; Guo-Guang Shao; Qun Wang; Xiaotao Qu; Bo Wang; Christopher Moy; Yue Fan; Zayed Albertyn; Xiayu Huang; Jingyu Zhang; Yang Qiu; Suso Platero; Matthew V Lorenzi; Enrique Zudaire; Jennifer Yang; Ying Cheng; Lin Xu; Yi-Long Wu
Journal:  Nat Commun       Date:  2019-04-16       Impact factor: 14.919

Review 6.  Rationale and Roadmap for Developing Panels of Hotspot Cancer Driver Gene Mutations as Biomarkers of Cancer Risk.

Authors:  Kelly L Harris; Meagan B Myers; Karen L McKim; Rosalie K Elespuru; Barbara L Parsons
Journal:  Environ Mol Mutagen       Date:  2019-10-06       Impact factor: 3.216

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.